Received Date : 31-Aug-2016

Revised Date : 10-Oct-2016

Accepted Date : 19-Oct-2016

Article type : Original Manuscript

Oral Swirl (OS) samples – A robust source of microRNA protected by extracellular vesicles

Tami Yap¹, Laura Vella², Christine Seers^{1,3}, Alf Nastri⁴, Eric Reynolds^{1,3}, Nicola Cirillo¹ Michael McCullough^{1,3}

¹ Melbourne Dental School, University of Melbourne, Victoria, Australia

² The Florey Institute for Neurosciences and Mental Health, Melbourne, Victoria, Australia

³ Oral Health Cooperative Research Centre, Victoria, Australia

⁴ Department of Oral and Maxillofacial Surgery, Royal Melbourne Hospital, Victoria, Australia

Running Title: Oral Swirl Samples – A robust source of microRNA

Corresponding Author:

Tami Yap

University of Melbourne – 720 Swanston Street Carlton VIC 3053

Email: tspyap@unimelb.edu.au

Phone: +61412669125

Fax: +61393411048

Word count: 2903

Date of submission: 01-09-16

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/odi.12603](https://doi.org/10.1111/odi.12603)

This article is protected by copyright. All rights reserved

Conflict of interest: None Declared

Abstract

MicroRNAs are small non-coding RNAs which are dysregulated in disease states, such as oral cancer. Extracellular vesicles, a potential source of microRNA, are found in saliva.

Objective: To demonstrate that a quantifiable amount of microRNA can be isolated from oral swirl samples. Additionally, we hypothesized that extracellular vesicles may protect contained microRNA from degradation in these samples.

Method: A polyethylene glycol based precipitation was used for extracellular vesicle enrichment of oral swirl samples. Comparison was made between samples treated with and without RNase. Further, samples from 3 subjects were submitted to a range of conditions over 7 days and assessed for presence of microRNA by reverse transcription quantitative PCR. Extracellular vesicles from samples were identified under transmission electron microscopy.

Results: An adequate quantity of microRNA for qPCR analysis was extractable from samples despite exposure to conditions under which degradation of RNA would be expected.

Conclusion: A technique was developed to isolate an adequate quantity of microRNA for analysis from oral swirl samples. Extracellular vesicle associated microRNA may be protected from degradation. This technique moves towards chairside application of translational microRNA research in the field of oral cancer prognostics.

Keywords: oral cancer, microRNA, extracellular vesicles, saliva

Abbreviations: OS, oral swirl; EVs, extracellular vesicles;

Introduction

The incidence of oral squamous cell carcinoma (OSCC) is increasing world-wide(Chaturvedi et al., 2013) and the five-year survival has changed little over the past 30 years(UK). The five-year survival is profoundly diminished for patients presenting with late stage tumours compared to those presenting with small, localized disease(Sciubba, 2001) . Furthermore, the effect of both the disease and treatment on appearance, speech, chewing, saliva and swallowing enormously impacts the patients' quality of life(Rogers et al., 2008).

The number of OSCCs that arise from precursor lesions is unknown, however reports indicate that 16–62% of OSCCs may develop from a potentially malignant oral mucosal disorder(Lee et al., 2000). At present, there are no established markers or laboratory studies that can detect OSCC prior to a clinically measurable tumour(Mydlarz et al., 2010).

Extracellular vesicles (EVs) have been investigated as a non-invasive source of potential prognostic and diagnostic biomarkers(Kim et al., 2014). EVs are a complex group of vesicles which originate from distinct sub-cellular compartments(Torrano et al., 2016). Exosomes are a specific type of EV that are 30–150 nm in diameter and released from many cell types. Exosomes are distributed widely within various biofluids, have a protective stable lipid membrane, may contain lipids, proteins, messenger RNAs (mRNAs) and microRNAs (miRNAs), and can be taken up by neighboring or distant cells as a means of intercellular communication(Pant et al., 2012, Sato-Kuwabara et al., 2015). In carcinogenesis, this may involve both cancer-promoting as well as cancer-protective cellular contents within both the tumour microenvironment or via the circulation to distant sites(Hannafon & Ding, 2013).

MicroRNAs are small non-coding RNAs, 18–22 nucleotides in length that mediate gene expression at the post-transcriptional level by degrading or repressing target mRNAs. Recent studies have showed that miRNAs are involved in numerous cellular processes, such as development, differentiation, proliferation, apoptosis, stress response, as well as cancer development(Mestdagh et al., 2008). Changes in miRNA expression have been associated with almost all types of human malignancies(Hui et al., 2009), and have been shown to be suitable for use as salivary biomarkers due to their ease of isolation and identification through quantitative PCR(Michael et al., 2010). The majority of miRNAs detectable in serum and saliva are reported to be within exosomes(Gallo et al., 2012). Salivary miRNAs have the potential to be both measurable biomarkers observable prior to clinically visible mucosal disease, as well as therapeutic targets.

The use of saliva for a clinically robust sampling method that can withstand time and temperature variability post-collection is attractive. However, presently whole saliva collection may take up to 30 minutes (Momen-Heravi et al., 2014), limiting its clinical adoption. Previous studies have used an oral rinse method of 10 mL of sterile saline or water to wet the patient's mouth for 30 seconds before collection in a sterile tube (Samaranayake et al., 1986, Borromeo et al., 1992). We have explored the use of an oral rinse method based upon these previous two methods that we will refer to as an oral swirl (OS).

The aim of the present study was to isolate EVs from OS samples for miRNA analysis and we hypothesized that extracellular vesicles may protect the contained miRNA from degradation. Thus, we assessed the robustness of this method for isolating miRNAs.

Methods

This study was approved by the Human Research Ethics Committee of the University of Melbourne (Ethics ID: 050900X).

OS sample collection

OS sample collection method involved requesting subjects to swirl 10 mL of sterile de-ionized water or PBS "like a mouthwash" for 60 seconds without swallowing and then expectorate into a sterile plastic tube. All OS samples were then centrifuged for 4 min at 4°C at 4000 x *g* to pellet epithelial cells and large particles. The remaining cell free swirl sample was stored at – 20°C.

Enriching for extracellular vesicles and RNA extraction

Initially, enrichment for EVs of 1 mL of cell-free OS was undertaken using either 40% polyethylene glycol PEG 6000 (Sigma-Aldrich, Castle Hill, NSW) in PBS 0.5M NaCl, or a proprietary EV precipitating reagent (Exoquick™). One mL aliquots of OS were mixed with either 1 mL of 40% PEG solution or 250 µL of Exoquick and placed overnight at 4°C. The samples were then centrifuged at 10,000 x *g* for 30 min before the supernatant was removed leaving approximately 100 µL of precipitant. RNA was extracted from the resultant 100 µL using the mirVana™ miRNA isolation kit (Life Technologies) and DNA removed using the Turbo DNA-free™ kit and measured by spectrophotometer (Nanodrop 2000c).

The PEG based method was enhanced by using 5 x 1 mL aliquots of 1 mL cell free OS placed with 1 mL of 40% PEG overnight at 4°C in a 2.2 mL micro-centrifuge tube. After centrifugation and discarding of the

supernatant as indicated above, the remaining five aliquots of 100 μ L were vortexed, pooled, centrifuged at 10,000 $\times g$ for 5 min and 400 μ L of the supernatant removed. This resulted in a 100 μ L precipitant from the original 5 $\times$ 1 mL aliquots. A pellet was not always visible. RNA was extracted from the resultant 100 μ L solution as previously described.

Transmission electron microscopy (TEM) of OS samples

OS samples were prepared using the PEG-based technique previously described. A 2 μ L aliquot was fixed in 10 μ L of 1% glutaraldehyde in PBS overnight at 4°C, and 6 μ L was absorbed onto glow discharged 300-mesh heavy-duty carbon-coated formvar Cu grids (ProSciTech, Kirwan, QLD, Australia) for 5 min, and excess was blotted on filter paper (Whatman, Maidstone, UK). Grids were washed twice with MilliQ water and stained with 2.5% uranyl acetate. Images were taken on a Tecnai G2 F30 (FEI, Eindhoven, The Netherlands) transmission electron microscope operating at 300 kV (Bio21 Molecular Science and Biotechnology Institute, University of Melbourne) (Figure 1).

RNase treatment challenge

Three 10 mL OS samples were collected from one subject, pooled and split into 6 $\times$ 5 mL aliquots. All samples were enriched for EVs using the protocol described above resulting in 6 EV concentrated technical replicate samples. RNase A was added to 3 replicates to reach a final concentration of 100 ng/ μ L in 100 μ L and incubated at 37°C for 10-15 min (analogous to protocols used to remove all RNA for DNA purification) to remove all free RNA (Cheng et al., 2014). RNA was then extracted from all samples using the mirVana™ miRNA isolation kit with one modification - the lysis buffer was substituted with TRI-Reagent™ (Sigma-Aldrich, Castle Hill, NSW, Australia). This substitution was intended to provide both inactivation of the RNase and lysis of EVs present. The remainder of the protocol was as per the mirVana™ kit protocol. The samples were then treated with Turbo DNA-free™ and measured by spectrophotometer. The samples were concentrated to 15 μ L using a rotational vacuum concentrator and measured using an Agilent 2100 Bioanalyzer using a small RNA chip (Figure 2.AB).

RNA was reverse transcribed using Megaplex™ RT Primers, Human Pool A v2.1 TaqMan® and the TaqMan® MicroRNA Reverse Transcription Kit before pre-amplification using Megaplex™ PreAmp Primers Human Pools A and TaqMan® PreAmp Master Mix. Quantitative PCR was performed using TaqMan® Fast Universal PCR Master Mix no AmpErase® UNG and a small RNA-specific TaqMan® MGB

probe for hsa-mir-24-5p (UGGCUAGUUCAGCAGGAACAG) (Figure 2.C). This miRNA was selected as it has been found to be a commonly isolated miRNAs in saliva samples (Park et al., 2009).

Thermal condition challenge

Seven 10 mL OS sample were collected on the same day within one hour from 3 individuals with no oral mucosal abnormalities. Cell free samples for each subject were subsequently divided into 14 x 5 mL aliquots and designated A1-A4, B1-B6 and C1-C4 (Figure 3). Samples A1 and A2 for each patient were immediately enriched for extracellular vesicles using the PEG based method described above and RNA extracted using the mirVana™ miRNA isolation kit and DNA removed using the Turbo DNA-free™ kit and measured by spectrophotometer. For the next 7 days, samples A3 and A4 were placed at room temperature (20°C), samples B1 and B2 were placed at -20°C, B3 and B4 were placed at 4°C and B5 and B6 were incubated at 37°C. Samples C1 and C2 were exposed to four temperature shifts from -20°C to +20 and C3 and C4 from 4°C to +20 over the next 7 days. Samples A3-C4 were subsequently enriched for EVs and RNA extracted as above. The samples were then reverse transcribed and quantitative PCR conducted as described previously.

Results

OS samples could easily be collected in a matter of minutes and multiple samples could be taken from one subject in one sitting. No statistical difference in RNA yield from EVs isolated from triplicate OS samples was found when comparing the use of deionized water (DW) with PBS (DW: $\mu = 5.37 \pm 1.87$ ng/ μ l s.d.; PBS $\mu = 3.97 \pm 0.20$ ng/ μ l; $p > 0.05$). Total RNA yield from EVs obtained using a 40% PEG solution protocol or the Exoquick™ protocol were similar with two matched samples enriched for EVs at the same time by both methods resulting in the first having 6.6 and 4.8 ng/ μ L and the second 4.4 and 5.1 ng/ μ L respectively .

Extracellular vesicular structures with observable lipid bilayer membranes consistent in size with exosomes were visualized using transmission electron microscopy (Figure 1). Majority of vesicular structures observed had such size characteristics.

Avoidance of complete RNA degradation by RNase prior to EV isolation was tested in cell free OS samples. Total RNA yield of samples treated with RNase ($\mu = 2.38 \pm 0.30$ ng/ μ L) was not statistically different to the non-RNase treated samples ($\mu = 2.95 \pm 0.52$ ng/ μ L; $p > 0.05$). Figure 2AB shows these same

samples measured for small RNAs (size range 6-150 nucleotides). The mean percentage of miRNA of small RNA for RNase treated samples ($\mu=40.3\pm6.1\%$) was not statistically different to non-RNase treated samples ($\mu=24.3\pm20.3\%$; $p>0.05$). The concentration of miRNA in small RNA for RNase treated samples ($\mu=493.5\pm147.5$ pg/ μ L) was additionally not statistically different to non-RNase treated samples ($\mu=275.4\pm366.7$ pg/ μ L; $p>0.05$). To confirm that miRNA were isolated in these samples, real time qPCR detection of hsa-mir-24 was undertaken. The result indicated that hsa-mir-24 abundance was not significantly different between preparations treated with RNase ($Cq \mu=26.2\pm0.07$) and the non-RNAs treated controls ($Cq \mu=25.6\pm1.35$; $p>0.05$)(Fig 2C). Thus, OS samples were protected from complete RNA degradation by RNase treatment prior to lysis of EVs. Interestingly, the RNase treated samples had a much more consistent Cq for hsa-mir-24 with a standard Cq deviation of only 0.07 across 6 samples.

Protection of OS samples from RNA degradation was further assessed by submitting cell free samples to thermal condition challenges for 7 days prior to EV enrichment and RNA extraction. OS samples were resistant to RNA degradation by thermal condition challenge even after 7 days. RNA yield varied between OS samples isolated from different subjects (Figure 4A), with some samples resulting in higher RNA yields than those immediately extracted, particularly those that were kept at room temperature or incubated at 37°C. Human versus microbial RNA was not differentiated at this step. The human microRNA, hsa-mir-24 was detected by real time PCR in samples submitted to all thermal conditions (Figure 4B). It can be seen that OS samples were protected from miRNA degradation by all thermal condition challenges, even after 7 days and repeated temperature changes. A slightly higher abundance (decrease in Cq values of RT-qPCR) can be seen when samples were either immediately extracted or kept frozen at -20°C compared with those incubated at a higher temperature, however no statistically significant differences were observed ($p>0.05$).

Discussion

We have developed a simple and robust method for isolating microRNA from cell-free OS samples by enriching these samples for EVs. The isolated EV-associated microRNA have been shown to be protected

from degradation and the microRNA is in sufficient quantity for assessment of variations that may be of clinical utility. This clearly demonstrates a simple and robust technique that is a significant step towards chairside application of translational microRNA research in the field of oral cancer prognostics.

The introduction of a clinical test requires balance between clinical benefit, and the time and additional skill required to administer it. Saliva, and saliva based clinical collection, is noninvasive and easy, and thus attractive. Overcoming the time limitation of collecting whole saliva and establishing a 'minimum required sample' for appropriate downstream analysis is desirable. Use of OS collection may provide a convenient sample source for biomarker analysis.

EVs have been shown to provide a protective and enriched source of microRNA compared to intracellular and cell-free blood(Cheng et al., 2014). The present study clearly demonstrates that they are protective of microRNA in oral swirls. Methods of OS handling and EV isolation developed here indicate that the use of OS for microRNA isolation for biomarker analysis will be a viable approach.

Novel compounded products for EV isolation can be costly. An easy to compose mixture which could be created and used at a low cost in any laboratory would encourage widespread availability and use of a test. The use of polyethylene glycol for viral and protein precipitation is an established methodology (Ingham, 1984, Lewis & Metcalf, 1988). EV precipitation using PEG is simple, cost- effective and avoids time consuming ultracentrifugation. The limitation of PEG is that it may allow for non-specific precipitation. This is particularly relevant to salivary samples as these are expected to contain a large amount of debris, including viral, bacterial and fungal elements, in addition to salivary components such as proteins. Such 'contamination' was clearly demonstrated when visualizing these samples with electron microscopy. Furthermore, submitted these samples to temperature challenge for 7 days showed an increase in nucleic acids for those samples left at room temperature or incubated at 37°C. This additional nucleic acid was likely bacterial or fungal, and as such it is therefore important that downstream analyses utilize tests highly specific for human biomarkers. In the present study we examined microRNA using human specific primers, confirming not only their presence, but that microRNA has been protected from degradation during thermal challenge. Thus, isolating assessable miRNA in the present study from OS samples after placement in various thermal conditions for 7 days is supportive that miRNA protection by EVs is a robust method that is temporally stable.

It would be expected that RNA present in salivary swirls would be degraded by RNase A unless there exists a barrier of protection within OS samples. Isolation of comparable quantities of RNA from samples treated and not treated with RNase suggests that the majority of miRNA in the OS samples were contained within EVs and that these EVs were protective of RNase degradation. The improved consistency in hsa-mir-24 qPCR Cq following RNase treatment may well be due to the degradation of extra-vesicular mRNA and microRNA, likely derived from lysed epithelial cells or free salivary RNA in the OS, thus resulting in the sampling of RNA derived solely from EVs. Further studies are required, but it would appear that the consistency of miRNA isolation using the EV isolation method developed in the present study shows significant promise for accurately and reproducibly measuring comparative abundances of OS derived microRNAs. Such a method is likely critical in the assessment of samples from patients with no mucosal abnormalities, those with inflammatory mucosal disease and those with oral cancer. It may well be that EV contained miRNA variation is observable in patients with OSCC prior to a lesion becoming clearly visible to the clinician.

Our study has demonstrated that utilizing a simple, non-invasive OS method allowed sufficient miRNA to be isolated for analysis. The method requires validation in individuals with a range of salivary flow rates and different oral mucosal disease's. Moreover, there is clearly the need to extend this OS method of collection, EV-enrichment and miRNA extraction to a prospective study and subsequently multicenter studies, so as to explore the usefulness of salivary EV miRNA variation for the early detection of OSCC.

Conclusion

The presence of exosome-sized extracellular vesicles has been demonstrated in OS samples. Assessable miRNA was able to be isolated in OS samples despite the sample being submitted to conditions expected to cause RNA degradation. EVs in OS samples may provide a stable source of miRNA for use as a biomarker, shielded from degradation. EV-enriched OS sampling may be the link to advance the clinical translation of miRNA in the prediction of OSCC development in individuals with and without potentially malignant oral mucosal disorders.

Acknowledgements

This work was supported by the Australian Dental Research Foundation, the Australia & New Zealand Head and Neck Cancer Society Research Foundation and the Oral Health Cooperative Research Centre.

Figure Legend

Figure 1. *Extracellular vesicular structures visualized by TEM in OS samples.* OS samples enriched for EVs were fixed and absorbed onto TEM grids. Extracellular vesicular structures with observable lipid bilayer membranes consistent in size with exosomes were visualized in OS samples.

Figure 2. *Preparations of OS enriched for EVs with and without exposure to RNase A before RNA extraction.* Six aliquots of OS samples were concentrated for EVs. Samples r1-r3 were treated with RNase A before RNA was extracted. Samples C4-6 were not RNase A treated. All samples were measured using a small RNA Agilent Bioanalyzer with electropherograms indicating the amount of microRNA, tRNA and small rRNA. (a) electropherogram for sample r1; (b) image generated from r1-3, C4-6 electropherograms; (c) C_q for hsa-mir-24 qPCR samples treated with RNase vs controls with mean and standard deviation.

Figure 3. OS samples were exposed to four daily temperature shifts (-20°C to 20°C and 4°C to 20°C) or stored at -20°C, 4°C, 20°C or 37°C over seven days prior to EV isolation and RNA extraction.

Figure 4. *RNA extracted from OS samples exposed to temperature challenges over seven days.*

OS samples were exposed to four daily temperature shifts (-20°C to 20°C and 4°C to 20°C) or stored at -20°C, 4°C, 20°C or 37°C over seven days prior to EV isolation and RNA extraction. (a) Total RNA content measured using a spectrophotometer; (b) microRNA has-mir-24 content assessed using RT-qPCR.

References

- Borromeo GL, McCullough MJ and Reade PC (1992). Quantitation and morphotyping of *Candida albicans* from healthy mouths and from mouths affected by erythematous candidosis. *J Med Vet Mycol* **30**: 477-80.
- Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, Rosenberg PS, Bray F and Gillison ML (2013). Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. *J Clin Oncol* **31**: 4550-9.
- Cheng L, Sharples RA, Scicluna BJ and Hill AF (2014). Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. *Journal of Extracellular Vesicles* **3**: 10.3402/jev.v3.23743.
- Gallo A, Tandon M, Alevizos I and Illei GG (2012). The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. *PLoS One* **7**: e30679.
- Hannafon BN and Ding WQ (2013). Intercellular Communication by Exosome-Derived microRNAs in Cancer. *International journal of molecular sciences* **14**: 14240-69.
- Hui AB, Shi W, Boutros PC, Miller N, Pintilie M, Fyles T, McCreedy D, Wong D, Gerster K, Waldron L, Jurisica I, Penn LZ and Liu FF (2009). Robust global micro-RNA profiling with formalin-fixed paraffin-embedded breast cancer tissues. *Laboratory investigation; a journal of technical methods and pathology* **89**: 597-606.
- Ingham KC (1984). Protein precipitation with polyethylene glycol. *Methods in enzymology* **104**: 351-6.
- Kim DK, Lee J, Kim SR, Choi DS, Yoon YJ, Kim JH, Go G, Nhung D, Hong K, Jang SC, Kim SH, Park KS, Kim OY, Park HT, Seo JH, Aikawa E, Baj-Krzyworzeka M, van Balkom BW, Belting M, Blanc L, Bond V, Bongiovanni A, Borrás FE, Buee L, Buzas EI, Cheng L, Clayton A, Cocucci E, Dela Cruz CS, Desiderio DM, Di Vizio D, Ekstrom K, Falcon-Perez JM, Gardiner C, Giebel B, Greening DW, Gross JC, Gupta D, Hendrix A, Hill AF, Hill MM, Nolte-'t Hoen E, Hwang DW, Inal J, Jagannadham MV, Jayachandran M, Jee YK, Jorgensen M, Kim KP, Kim YK, Kislinger T, Lasser C, Lee DS, Lee H, van Leeuwen J, Lener T, Liu ML, Lotvall J, Marcilla A, Mathivanan S, Moller A, Morhayim J, Mullier F, Nazarenko I, Nieuwland R, Nunes DN, Pang K, Park J, Patel T, Pocsfalvi G, Del Portillo H, Putz U, Ramirez MI, Rodrigues ML, Roh TY, Royo F, Sahoo S, Schiffelers R, Sharma S, Siljander P, Simpson RJ, Soekmadji C, Stahl P, Stensballe A, Stepien E, Tahara H, Trummer A, Valadi H, Vella LJ, Wai SN, Witwer K, Yanez-Mo M, Youn H, Zeidler R and Gho YS (2014). EVpedia: a community web portal for extracellular vesicles research. *Bioinformatics (Oxford, England)*.

Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, Benner SE, Xu XC, Lee JS, Papadimitrakopoulou VM, Geyer C, Perez C, Martin JW, El-Naggar AK and Lippman SM (2000). Predicting cancer development in oral leukoplakia: ten years of translational research. *Clinical cancer research : an official journal of the American Association for Cancer Research* **6**: 1702-10.

Lewis GD and Metcalf TG (1988). Polyethylene glycol precipitation for recovery of pathogenic viruses, including hepatitis A virus and human rotavirus, from oyster, water, and sediment samples. *Applied and environmental microbiology* **54**: 1983-8.

Mestdagh P, Feys T, Bernard N, Guenther S, Chen C, Speleman F and Vandesompele J (2008). High-throughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. *Nucleic acids research* **36**: e143.

Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, Illei GG and Alevizos I (2010). Exosomes from human saliva as a source of microRNA biomarkers. *Oral Dis* **16**: 34-8.

Momen-Heravi F, Trachtenberg AJ, Kuo WP and Cheng YS (2014). Genomewide Study of Salivary MicroRNAs for Detection of Oral Cancer. *J Dent Res* **93**: 86s-93s.

Mydlarz WK, Hennessey PT and Califano JA (2010). Advances and Perspectives in the Molecular Diagnosis of Head and Neck Cancer. *Expert opinion on medical diagnostics* **4**: 53-65.

Pant S, Hilton H and Burczynski ME (2012). The multifaceted exosome: biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. *Biochemical pharmacology* **83**: 1484-94.

Park NJ, Zhou H, Elashoff D, Henson BS, Kastratovic DA, Abemayor E and Wong DT (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. *Clinical cancer research : an official journal of the American Association for Cancer Research* **15**: 5473-7.

Rogers SN, Scott J, Chakrabati A and Lowe D (2008). The patients' account of outcome following primary surgery for oral and oropharyngeal cancer using a 'quality of life' questionnaire. *European journal of cancer care* **17**: 182-8.

Samaranayake LP, MacFarlane TW, Lamey PJ and Ferguson MM (1986). A comparison of oral rinse and imprint sampling techniques for the detection of yeast, coliform and Staphylococcus aureus carriage in the oral cavity. *Journal of oral pathology* **15**: 386-8.

Sato-Kuwabara Y, Melo SA, Soares FA and Calin GA (2015). The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). *International journal of oncology* **46**: 17-27.

Sciubba JJ (2001). Oral cancer. The importance of early diagnosis and treatment. *Am J Clin Dermatol* **2**: 239-51.

Torrano V, Royo F, Peinado H, Loizaga-Iriarte A, Unda M, Falcón-Perez JM and Carracedo A (2016).

Vesicle-MaNiA: extracellular vesicles in liquid biopsy and cancer. *Current opinion in pharmacology* **29**: 47-53.

UK CR.

Author Manuscript

odi_12603_f1.tif

odi_12603_f2.tif

Author Manuscript

a **b**

Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Yap, T;Vella, LJ;Seers, C;Nastri, A;Reynolds, E;Cirillo, N;McCullough, M

Title:

Oral swirl samples - a robust source of microRNA protected by extracellular vesicles

Date:

2017-04-01

Citation:

Yap, T., Vella, L. J., Seers, C., Nastri, A., Reynolds, E., Cirillo, N. & McCullough, M. (2017). Oral swirl samples - a robust source of microRNA protected by extracellular vesicles. ORAL DISEASES, 23 (3), pp.312-317. <https://doi.org/10.1111/odi.12603>.

Persistent Link:

<http://hdl.handle.net/11343/292256>